CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data

OSE Immunotherapeutics' CEO Nicolas Poirier talks about the company's IL-7 receptor agonist, lusvertikimab, recent data presented at The European Crohn's and Colitis Organization congress, commercialization and development strategy and the future of IBD therapy.

Episode metadata supplied by the publisher feed · Published Apr 3, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data

0:00 16:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 16 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on April 3, 2025.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!